trial

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCTId NCT03943537
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 87 (actual)
Sponsored by Mclean Hospital
Primary completion 2024-02-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
87 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-10-01
Primary completion
2024-02-23
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Intranasal Insulin

Sponsors

Mclean HospitalLead Sponsor

Investigators

1
Virginie-Anne Chouinard, M.D.Principal Investigator

Sites

1 total
Belmont, United States

Linked catalysts

1
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients — primary completion2024-02-23

Facts & assertions

4 sourced
Enrollment
87
Phase
PHASE2
Primary Completion Date
2024-02-23
Status
COMPLETED
relationships
The graph out of here
drug
Intranasal Insulin
drug
lead_sponsor
Mclean Hospital
company
indication
Schizo Affective Disorder
indication
Insulin Resistance
indication
Psychosis
indication
investigator
Virginie-Anne Chouinard, M.D.
person